贝伐珠单抗 (bev)/奥拉帕尼 (ola) 维持方案被批准用于 BRCA1/2 突变 (BRCAmut) 和同源重组缺陷 (HRD) 高级别晚期卵巢癌 (AOC) 一线治疗，基于进展显着改善 -在 PAOLA-1/ENGOT-ov25 试验 (NCT02477644) 中，与单独使用 Bev 进行比较，其中 HRD 通过 MyChoice CDx PLUS 测试检测到。学术上的shallowHRDv2测试是基于浅层全基因组测序而开发的，作为MyChoice的替代品。介绍了在 449 个 PAOLA-1 肿瘤样本上，shallowHRDv2 与 MyChoice 相比的分析和临床有效性。 shallowHRDv2 和 MyChoice 之间的总体一致性为 94% (369/394)。与 MyChoice (51/449; 11%) 相比，shallowHRDv2 (15/449; 3%) 观察到的非贡献测试较少。根据shallowHRDv2（包括BRCAmut）的HRD肿瘤患者，与bev相比，使用bevola的PFS显着延长（中位PFS：65.7个月与20.3个月，风险比（HR）：0.36 [95% CI：0.24-0.53]）。这种益处对于 BRCA1/2 野生型肿瘤也很显着（40.8 个月与 19.5 个月，HR：0.45 [95% CI：0.26-0.76]）。 ShallowHRDv2 是一种高性能、经过临床验证且经济高效的 HRD 检测测试。© 2023。作者。

The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the PAOLA-1/ENGOT-ov25 trial (NCT02477644), where HRD was detected by MyChoice CDx PLUS test. The academic shallowHRDv2 test was developed based on shallow whole-genome sequencing as an alternative to MyChoice. Analytical and clinical validities of shallowHRDv2 as compared to MyChoice on 449 PAOLA-1 tumor samples are presented. The overall agreement between shallowHRDv2 and MyChoice was 94% (369/394). Less non-contributive tests were observed with shallowHRDv2 (15/449; 3%) than with MyChoice (51/449; 11%). Patients with HRD tumors according to shallowHRDv2 (including BRCAmut) showed a significantly prolonged PFS with bev+ola versus bev (median PFS: 65.7 versus 20.3 months, hazard ratio (HR): 0.36 [95% CI: 0.24-0.53]). This benefit was significant also for BRCA1/2 wild-type tumors (40.8 versus 19.5 months, HR: 0.45 [95% CI: 0.26-0.76]). ShallowHRDv2 is a performant, clinically validated, and cost-effective test for HRD detection.© 2023. The Author(s).